| Literature DB >> 16412231 |
Thomas Fillies1, Richard Werkmeister, Jens Packeisen, Burkhard Brandt, Philippe Morin, Dieter Weingart, Ulrich Joos, Horst Buerger.
Abstract
BACKGROUND: Intermediary filaments are involved in cell motility and cancer progression. In a variety of organs, the expression of distinct intermediary filaments are associated with patient prognosis. In this study, we seeked to define the prognostic potential of cytokeratin and vimentin expression patterns in squamous cell carcinomas (SCC's) of the oral cavity.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16412231 PMCID: PMC1379654 DOI: 10.1186/1471-2407-6-10
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Antibodies, company, clone, pre-treatment and dilution of used antibodies.
| Ck 5/6 | DAKO, Glostrup, Denmark | D5/16B4 | Autoclave 10 min | 1 : 80 |
| Ck 8/18 | Dianova, Hamburg, Germany | K8.8/DC10 | Autoclave 10 min, citrate buffer | 1 : 40 |
| Ck 1 | Novocastra, Newcastle, UK | 34βB4 | Steamer 30 min, citrate buffer | 1 : 150 |
| Ck 10 | DAKO, Glostrup, Denmark | DE-K10 | Steamer 30 min, citrate buffer | 1 : 400 |
| Ck 14 | Dianova Hamburg, Germany | LL002 | Steamer 30 min, citrate buffer | 1 : 50 |
| Ck 19 | Quartett GmbH, Berlin, Germany | KS19.1 | Steamer 30 min, citrate buffer | 1 : 80 |
| Vimentin | Ventana Inc., Tucson, USA | V9 | Steamer 30 min, citrate buffer | 1 : 1000 |
Tumour patient cases in this study
| Age (mean) | 58 years (range 31 – 90 years) |
| Sex | 240 men, 68 women |
| Follow-up (mean) | 64 months (range 4 – 181 months) |
| T stadium | 135 T1 tumours |
| 125 T2 tumours | |
| 15 T3 tumours | |
| 33 T2 tumours | |
| N stadium | 212 N0 lymph node negative |
| 57 N1 lymph node positive carcinoma | |
| 39 N2 lymph node positive carcinoma | |
| Grading | 54 well differentiated tumours (G1) |
| 214 moderately differentiated tumours (G2) | |
| 40 weakly differentiated tumours (G3) |
Expression profile of cytokeratins
| Antibody | No Expression | postive Expression |
| CK 5/6 | 123 | 169 |
| CK8/18 | 133 | 154 |
| CK 1 | 147 | 121 |
| CK 10 | 177 | 91 |
| CK14 | 159 | 107 |
| Ck 19 | 149 | 107 |
| Vimentin | 237 | 24 |
Figure 1Immunohistochemical staining of oral squamous cell carcinoma with cytokeratin cytokeratin antibodies. a) cytokeratin 5/6 Antibody (magnification 20×) b) cytokeratin 19 antibody (magnification 20×) c) cytokeratin 8/18 antibody (Magnification 10×) d) cytokeratin 8/18 antibody (magnification 20×) e) cytokeratin 14 antibody (magnification 20×) d) cytokeratin 14 antibody (magnification 20×).
Chi-square Test of Ck 5–6 and Ck 14
| Prognosticator | Node status P value | Tumour size P value |
| Ck 5–6 | 0.045 | 0.026 |
| Ck 14 | 0.021 | 0.037 |
Figure 2Overall survival of patient with oral squamous cell carcinoma in dependence on Cytokeratin 8–18 expression calculated by the Kaplan-Meier method.
Figure 3Overall survival of patient with oral squamous cell carcinoma in dependence on Cytokeratin 19 expression calculated by the Kaplan-Meier method.
Figure 4Overall survival of patient with nodal negative oral squamous cell carcinoma in dependence on Cytokeratin 8–18 expression calculated by the Kaplan-Meier method.
Multivariate analysis of the time of survival in relation to the Cytokeratins expression and other prognostic factors
| Prognosticator | P valuea | RRb | Confidance intervalc |
| Tumor size | 1.239 | 1.0–1.5 | |
| Nodal status | 1.866 | 1.4–2.4 | |
| CK5/6 | 0.350 | 1.167 | 0.8–1.6 |
| CK1 | 0.931 | 0.985 | 0.7–1.4 |
| CK10 | 0.852 | 0.968 | 0.7–1.4 |
| CK19 | 0.227 | 1.163 | 0.9–1.5 |
| CK14 | 0.470 | 0.872 | 0.6–1.3 |
| CK8/18 | 1.487 | 1.1–2.1 |
a The partially nonparametric regression model of Cox (1972) was used to evaluate the predictive power of vatious combinations of prognosticators in a multivariate manner.
b RR, relative risk
c 95% confidence interval